Original Report

Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis


 

Background Little is known about the informational needs and quality of life (QOL) of patients with metastatic breast cancer (MBC) within the first year of their diagnosis.

Objective To describe the informational needs and QOL of patients with MBC within the first year of diagnosis, and to identify sociodemographic and medical factors that may be associated with informational needs and QOL.

Methods 52 patients (50 women, 2 men) enrolled within a year of diagnosis of MBC completed a cross-sectional, self-administered paper survey that included patient demographics, the Toronto Informational Needs Questionnaire-Breast Cancer (TINQ), the Hospital Anxiety and Depression Scale (HADS), and Medical Outcomes Study Short Form-36 (SF-36). High informational need was defined as a TINQ score of ≥ 200.

Results Of the total 52 patients, 69% (35/52) had high informational needs, 20% met the criteria for anxiety (HADS-Anxiety score, ≥ 11), and 8% met the criteria for depression. SF-36 scores were lower in all 8 subscales compared with the general population. Multivariate analyses showed that patients who were married or living as married (OR, 6.1; 95% CI, 1.4-28.9) and patients with de novo MBC (OR, 2.8; 95% CI, 0.5-14.3) or a shorter disease-free interval (DFI; < 5 years; OR, 24.2; 95% CI, 3.1-187.4) were more likely to have more informational needs (C statistic, 0.824) than were patients with a longer DFI (≥ 5 years).

Limitations This is a small cross-sectional study of a single academic institution.

Conclusion Patients with recently diagnosed MBC have high informational needs and decreased overall QOL. Additional research and supportive services meeting the informational and psychosocial needs of patients living with MBC are warranted.

Funding Metastatic Research Fund (anonymous donor), the Megan Lally Memorial Fund, the Nancy and Randy Berry Junior Faculty Award, the Karen Webster & David Evans Metastatic Research Fund, and the Susan G Komen for the Cure.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Young and BRCA positive: Now what?
MDedge Hematology and Oncology
Widespread BRCA1/BRCA2 screening recommendation draws praise, fire
MDedge Hematology and Oncology
Dose-dense chemo aids high-risk breast cancer patients
MDedge Hematology and Oncology
VIDEO: Women with node-positive breast cancer benefit from dose-dense chemo
MDedge Hematology and Oncology
Genetic screen not worth cost for node-negative breast cancer patients
MDedge Hematology and Oncology
20-year follow-up supports adjuvant radiotherapy for DCIS
MDedge Hematology and Oncology
Should ductal carcinoma in situ be treated?
MDedge Hematology and Oncology
VIDEO: Liquid tumor biopsies await prospective validation
MDedge Hematology and Oncology
Liquid biopsies: High potential but are they ready for prime time?
MDedge Hematology and Oncology
Turning back the clock: the increase in bilateral mastectomies
MDedge Hematology and Oncology